Guide
What to expect during GLP-1 therapy — nausea, GI effects, dehydration, plateau, and rare adverse events.
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produce a predictable side-effect profile. Most effects are gastrointestinal, dose-dependent, and resolve as patients titrate slowly. This guide covers what to expect at each phase of treatment and when to call your clinician.
The most common side effects across both semaglutide and tirzepatide trials are nausea (reported by 30-45% of patients), diarrhea (15-25%), constipation (15-25%), vomiting (10-20%), and abdominal pain. Effects peak in the first 1-2 weeks after a dose increase and then taper. The majority are mild to moderate and resolve without intervention.
Slow titration is the single most effective tool for reducing GI burden. If your provider lets you stay at a tolerable dose for an extra 2-4 weeks before stepping up, take it. The endpoint is the same; the path is more comfortable.
Reduced fluid intake plus GI losses creates a dehydration risk. Aim for 80-100 oz of fluid daily during titration. Electrolyte support (sodium, potassium, magnesium) helps with the constipation/diarrhea cycle and reduces headaches and fatigue some patients report. If you cannot keep fluids down for more than 24 hours, contact your clinician.
Practical electrolyte targets: sodium 2-3 g/day, potassium 3-4 g/day, magnesium 400 mg/day. An electrolyte powder once or twice daily during titration covers most of this.
Weight-loss plateaus between weeks 12 and 24 are common and not a sign of failure. The body's adaptive thermogenesis reduces resting energy expenditure as weight drops. Strategies that help: dose escalation if your provider agrees, resistance training to preserve and build lean mass, protein intake at 0.7-1.0 g per pound of goal body weight, and a careful look at sleep and stress.
Pancreatitis is rare but serious. Call your clinician immediately for severe abdominal pain that radiates to the back, with or without vomiting. Gallstones occur more frequently with rapid weight loss. Diabetic retinopathy can transiently worsen in patients with longstanding diabetes. Medullary thyroid carcinoma is a black-box warning for GLP-1s based on rodent studies; the human signal is unconfirmed but patients with personal or family history of MTC or MEN-2 should not take these drugs.
Severe or persistent abdominal pain, persistent vomiting more than 24 hours, signs of dehydration (dizziness, dark urine, low urine output), severe headache, vision changes, signs of an allergic reaction (hives, throat tightness, swelling), or pregnancy. Mild nausea, mild GI changes, mild fatigue, and injection-site reactions are usually managed at home with hydration and time.
Most GI effects peak in the first 7-14 days after a dose increase and resolve within 2-4 weeks. Effects that persist beyond that warrant a clinician conversation about slowing titration or pausing.
Many providers will prescribe ondansetron for the first 1-2 weeks of titration. This is a clinician decision based on your medical history.
Each titration step partially resets the GI adaptation. The trade-off is greater appetite suppression and weight loss at the higher dose. Slow titration cushions the bump.
Most GLP-1 side effects are uncomfortable but not dangerous. The exceptions are listed in the 'less common but serious' section above. Severe abdominal pain, persistent vomiting, signs of dehydration, or vision changes are reasons to call your clinician promptly.
For physician-led GLP-1 care at $199/mo flat-rate compounded sema, our 2026 editor's pick is NexLife. LegitScript-certified, Forbes-ranked, money-back warranty. Visit NexLife →
Editorial note. This guide is for educational purposes only and does not constitute medical advice. Always consult a licensed clinician about your specific situation.